intellegens

Imputation of assay activity data using deep learning

Gareth Conduit

Alchemite™ machine learning tool to

Reduce the need for experiments and **accelerate** drug discovery

Utilise **all available** information: computer simulations and real-life measurements

Impute values from sparse data

Broadly applicable with **proven** applications in drug design and materials discovery

Novartis dataset to benchmark machine learning

159 kinase proteins, 10000 compounds, data 5% complete



Data from ChEMBL
Martin, Polyakov, Tian, and Perez,
J. Chem. Inf. Model. 57, 2077 (2017)

Validate imputation of missing entries

Realistically split holdout data set, extrapolate to new chemical space



Impute missing entries in new chemical space



● Training

★ Validation

Data from ChEMBL
Martin, Polyakov, Tian, and Perez,
J. Chem. Inf. Model. 57, 2077 (2017)

QSAR: quantitative structure-activity relationships





Molecular weight=183 Da



Train off one column at a time

Standard methods learn descriptor-protein correlations



Train and predict one column at a time



Alchemite™ uses all available data

Include protein-protein correlations



Validate imputation of missing entries

Realistically split holdout data set, extrapolate to new chemical space, and calculate the accuracy



Alchemite™ outperforms other methods



Calculate probability distribution



Less confident prediction



Focus on most confident predictions



Reporting on only most confident predictions



Select performance level



Taking Alchemite™ to market

Intellegens

optibrium

Optibrium and Intellegens Collaborate to Apply Novel Deep Learning Methods to Drug Discovery

Partnership combines Intellegens' proprietary AI technology with Optibrium's expertise in predictive modelling and compound design

optibrium

Intellegens

CATAPULT
Medicines Discovery

Cambridge duo in £1m AI drug discovery project

Cambridge duo Optibrium and Intellegens along with Medicines Discovery Catapult in Cheshire have secured a grant from Innovate UK to fund a £1 million project investigating Artificial Intelligence support for drug discovery.

Open Source Malaria competition



OPEN SOURCE MALARIA

Looking for New Medicines

Open Source Malaria entrants

Entrant	Precision	Result
Molomics	82%	**Winner (company)**
Davy Guan	82%	**Winner (non-company)**
Optibrium/Intellegens	81%	**Second place**
Exscientia	81%	**Second place**
Slade Matthews	64%	Runner-up
Auromind	58%	Runner-up
Raymond Lui	58%	Runner-up
KCL	36%	Runner-up
Interlinked TX	36%	Runner-up

Focus on compounds with low uncertainty



Open Source Malaria experimental validation



Optibrium/Intellegens

0.647 µM

Open Source Malaria other compounds



Optibrium/Intellegens
0.647 µM



Davy Guan
>25 µM



Exscientia
10.9 µM



Molomics
>25 µM

Open Source Malaria other compounds



Summary

Alchemite™ trains across all endpoints to capture activity–activity correlations

Understand and exploit probability distribution to focus on most confident results

Impute results of missing assays to high accuracy, enabling computational screening of compounds to identify new hits

Take Alchemite™ to market with Optibrium in October 2020

intellegens

optibrium

gareth@intellegens.ai